KALY (Kali, Inc.) Soars on Hemp4mula CBD Infused Chewing Gum Order
December 17 2018 - 11:29AM
InvestorsHub NewsWire
BY BOE
RIMES ON DECEMBER 17, 2018
InvestorsHub NewsWire -- KALY (Kali, Inc.) is exploding up the
charts after the Company announced a $100,000 wholesale order of
its Hemp4mula CBD Infused Chewing Gum. The wholesale buyer plans to
have Hemp4mula CBD Infused Chewing Gum available for sale at select
retail drugstore locations and through the soon to be launched USMJ
E-commerce Site. Earlier this month, Kali-Extracts announced
launching its own line of hemp-derived CBD infused candies and
vapes under the brand name Hemp4mula. Kali-Extracts Hemp4mula CBD
Infused Chewing Gum will come in a blister back of 8 pieces with 10
mg each of hemp-derived CBD. Kali-Extracts expects to soon produce
hemp-derived CBD infused mints and gummies. Hemp4mula vapes are
anticipated to be in production early next year. Investors should
be aware that KALY has a skull & crossbones designation from
OTCMarkets.
Earlier this year KALY acquired NCM Biotech. NCM Biotech
has developed a patented cannabis extraction process – U.S. Patent
No. 9,199,960 entitled “METHOD AND APPARATUS FOR PROCESSING
HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT.”
NCM’s process has been engaged in a number of medical and
pharmaceutical research and development projects in addition to
being licensed to Puration, Inc. (USOTC: PURA) for commercial
applications.
The acquisition plans contemplate NCM management assuming the
senior management positions at Kali in conjunction with the planned
acquisition. NCM Biotech’s medical advisory team includes John N.
Gaitanis, MD., Director of Child Neurology at Tufts Medical
Center/Floating Hospital for Children; Lloyd R. Saberski,
M.D., Associate Professor of Anesthesiology and Chronic Pain
Management, Yale University, and John McMichael, Ph.D., President
& CEO Beech Tree Labs.
Kali plans to pursue pharmaceutical and other commercial
applications of its patented extraction process building on the
success of its current research projects and its success with
Puration. Kali maintains assets and operations today in the marina
management business of which it plans to divest in conjunction with
the planned acquisition of NCM Biotech.
On October 29 KALY announced entering into discussions with
Puration, Inc. and Nouveau Life Pharmaceuticals, Inc. to explore
forming a joint venture company between the three to develop
cannabis pharmaceutical products. Frederick Ferri, CEO and Founder
of NCM Biotech notes, “Some feedback has specifically indicated
that a number of our candidate pharmaceutical products under
development have a greater efficacy potential than GW
Pharmaceutical [GWPH] products and candidate products.“
Several days ago KALY announced a letter to shareholders to
further confirm recent announcements from the company and to
outline measures underway to update its public disclosures. On
November 15 [th], the company announced the acquisition of NCM
Biotech in a transaction that changed the business direction of the
company. Prior to that acquisition, the company’s previous business
focus on marina management had languished. In addition to the
marina management business not advancing as originally planned, the
company had fallen behind in the timely filing of the disclosures
required by OTCMarkets. Accordingly, OTCMarkets had posted a
“stop-sign” icon on the KALY OTCMarkets page to warn investors that
the company was not current in its required filings and to take
appropriate precautions in investment decisions associated with
KALY. Yesterday, December 13, 2018, OTCMarkets updated its
precautionary notice regarding KALY to a Caveat Emptor icon to
further raise investor precaution in regard to investment decisions
associated with KALY. The letter today is intended to confirm the
recent announcements made in conjunction with the November 15
[th]acquisition and the company’s corresponding new business
direction, in addition to addressing efforts underway to bring all
KALY’s required disclosures current with OTCMarkets standards. The
letter is included in its entirety below.
KALY recently acquired a biotech company with a patented
cannabis extraction process. Accordingly, KALY updated its overall
business plan (a presentation on the company’s updated business
plan is available on KALY’s website). Hemp4mula is part of the
updated business plan which management is rapidly executing. The
company recently announced a $300,000 hemp-derived CBD extraction
contract with Puration, Inc. The CBD Kali-extracts it will produce
is to support PURA’s contract to produce a private labeled CBD
infused Water for Generex Biotechnology.
Currently trading at a $1.6 million market
valuation KALY currently has a skull and crossbones
designation from OTCMarkets. KALY is an exciting story developing
in small caps; the Company is making some big moves recently
acquiring NCM Biotech and launching its own line of hemp-derived
CBD infused candies and vapes under the brand name Hemp4mula.The
stock is running up the charts after KALY announced a $100,000
wholesale order of its Hemp4mula CBD Infused Chewing
Gum. We will be updating on KALY when more details
emerge so make sure you are subscribed to Microcapdaily so you know
what’s going on with KALY.
MicroCap Daily also featured articles today
on Charlotte’s Web Holdings Inc (OTCMKTS: CWBHF), and
Endonovo Therapeutics Inc (OTCMKTS: ENDV).
Original Source:
tps://www.microcapdaily.com/kaly-kali-inc-soars-on-hemp4mula-cbd-infused-chewing-gum-order/122792/
Republished by NextBigTicker.com
Charlottes Web (QX) (USOTC:CWBHF)
Historical Stock Chart
From Aug 2024 to Sep 2024
Charlottes Web (QX) (USOTC:CWBHF)
Historical Stock Chart
From Sep 2023 to Sep 2024